How did RKDA's revenue and expenses shift in Q4 2024?

Arcadia Biosciences Inc (RKDA) experienced a notable increase in revenue and certain expenses in Q4 2024, reflecting strategic shifts and operational adjustments. 1. **Revenue Growth**: RKDA's revenue rose by 3.9% to $1.22 million in Q4 2024, up from the previous year's $1.18 million. This growth was primarily driven by the significant sales increase of Zola coconut water, which saw a 55% year-over-year rise. Zola's retail store count expanded by 68%, and its distribution gained marked traction, outpacing the coconut water category growth. 2. **Operating Expense Dynamics**: Despite the revenue growth, Arcadia Biosciences Inc faced increased expenses. The SG&A (Selling, General, and Administrative) expenses amounted to approximately $2.2 million, including $380,000 attributed to transition costs from the sale of GoodWheat, indicating a 20% rise compared to the previous year. Research and Development (R&D) costs increased by $9,000, reaching $24,000. The company's cash usage decreased to $1.5 million, marking the lowest level since going public, including $430,000 allocated to discontinued operations. 3. **Financial Position**: At the end of Q3 2024, Arcadia Biosciences Inc held $6.6 million in cash and short-term investments, a decrease from $8.1 million at the end of Q2 2024. The inventory balance decreased by 15% to $835,000. The cost of revenues included a $150,000 write-down related to hemp and GoodWheat seed. In conclusion, RKDA's Q4 2024 financials showed a positive revenue uptick, especially in the Zola coconut water segment, alongside strategic expenses linked to business transitions. However, the company also faced challenges with increased SG&A costs and a decrease in cash reserves compared to the previous quarter.